FDA Approves CYTARABINE — Hospira, Inc.

Hospira, Inc. received approval on June 4, 1990, for its intrathecal formulation of CYTARABINE (ANDA071868), a critical therapeutic addressing the significant unmet market demand for this active pharmaceutical ingredient in the oncology sector. This authorization is expected to strengthen Hospira’s established presence in the legacy generic market and diversify its product portfolio by enabling entry into high-margin central nervous system delivery segments.